Literature DB >> 34956494

Peripheral blood lymphocyte counts in patients with infectious mononucleosis or chronic active Epstein-Barr virus infection and prognostic risk factors of chronic active Epstein-Barr virus infection.

Jiancheng Lin1, Xiaokang Chen1, Haiming Wu1, Xiaoyun Chen1, Xiaomei Hu1, Jin Xu2.   

Abstract

OBJECTIVE: To explore the peripheral blood lymphocyte counts and analyze the prognostic risk factors for the death in patients with chronic active Epstein-Barr virus (CAEBV) infection.
METHODS: Clinical data of 64 patients infected with CAEBV (CAEBV group) and 64 patients with infectious mononucleosis (IM group) in our hospital were retrospectively analyzed. Meanwhile, 64 healthy individuals came for physical examination were enrolled in the control group. The three groups were compared for white blood cell count, lymphocyte count, and levels of peripheral blood NK cells, B cells, CD3+, CD4+, CD8+, CD4+CD28+, CD8+CD28+, CD4+CD25+, DR+CD8+, CD38+CD8+, CD4+ and CD8+ naive T cells and subsets of memory T cells. Patients infected with CAEBV were further divided into a survival subgroup and a death subgroup according to the survival outcome. The data were processed using univariate analysis and multivariate logistic regression analysis.
RESULTS: Compared with the control group, the IM group had higher levels of white blood cell count, lymphocyte count, CD3+, CD4+, CD8+, CD4+CD25+, DR+CD8+, CD38+CD8+, effector-memory CD4+CD62L-CD45RO+ and effector-memory CD8+CD62L-CD45RO+, but lower levels of NK cells, B cells, CD4+CD28+, CD8+CD28+, naive CD4+CD62L+CD45RA+ and naive CD8+CD62L+CD45RA+ (all P<0.05). Compared with the control group, the CAEBV group had lower levels of white blood cell count, lymphocyte count, CD3+, CD4+, CD8+, NK cells, B cells, CD4+CD28+, CD8+CD28+, naive CD4+CD62L+CD45RA+ and naive CD8+CD62L+CD45RA+, but higher levels of CD4+CD25+, DR+CD8+, CD38+CD8+, effector-memory CD4+CD62L-CD45RO+ and effector-memory CD8+CD62L-CD45RO+ (all P<0.05). Univariate analysis and multivariate logistic regression analysis showed that EBV DNA>105 copies/mL, platelet count <50×1012/L, albumin <30 g/L and serum ferritin >5000 μg/L were independent risk factors for the death of patients with CAEBV.
CONCLUSION: Patients infected with CAEBV showed imbalance of lymphocyte subsets and immune dysfunction. EBV DNA>105 copies/mL, platelet count <50×1012/L, albumin <30 g/L and serum ferritin >5000 μg/L are risk factors of death in patients with CAEBV. AJTR
Copyright © 2021.

Entities:  

Keywords:  Chronic active Epstein-Barr virus; lymphocyte subsets; peripheral blood; prognosis

Year:  2021        PMID: 34956494      PMCID: PMC8661241     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  24 in total

Review 1.  Oncogenesis of CAEBV revealed: Intragenic deletions in the viral genome and leaky expression of lytic genes.

Authors:  Takayuki Murata; Yusuke Okuno; Yoshitaka Sato; Takahiro Watanabe; Hiroshi Kimura
Journal:  Rev Med Virol       Date:  2019-12-17       Impact factor: 6.989

Review 2.  EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.

Authors:  Jorge J Castillo; Brady E Beltran; Roberto N Miranda; Ken H Young; Julio C Chavez; Eduardo M Sotomayor
Journal:  Am J Hematol       Date:  2018-07       Impact factor: 10.047

3.  NK-cell post-transplant lymphoproliferative disease with chronic active Epstein-Barr virus infection-like clinical findings.

Authors:  Tomoki Iemura; Tadakazu Kondo; Masakatsu Hishizawa; Kouhei Yamashita; Hiroshi Kimura; Akifumi Takaori-Kondo
Journal:  Int J Infect Dis       Date:  2019-08-06       Impact factor: 3.623

4.  Shift in Epstein-Barr virus (EBV)-infected cells in chronic active EBV disease.

Authors:  Shinichiro Sakaki; Ken-Ichi Imadome; Fuyuko Kawano; Hisaya Nakadate; Akira Ishiguro
Journal:  Pediatr Int       Date:  2019-08-21       Impact factor: 1.524

5.  Interferon alpha as antiviral therapy in chronic active Epstein-Barr virus disease with interstitial pneumonia - case report.

Authors:  Jacek Roliński; Ewelina Grywalska; Aleksandra Pyzik; Michał Dzik; Violetta Opoka-Winiarska; Agata Surdacka; Maciej Maj; Franciszek Burdan; Michał Pirożyński; Piotr Grabarczyk; Elżbieta Starosławska
Journal:  BMC Infect Dis       Date:  2018-04-20       Impact factor: 3.090

Review 6.  Epstein-Barr virus and its association with disease - a review of relevance to general practice.

Authors:  Anders Fugl; Christen Lykkegaard Andersen
Journal:  BMC Fam Pract       Date:  2019-05-14       Impact factor: 2.497

7.  Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.

Authors:  Rou-Jun Peng; Bo-Wei Han; Qing-Qing Cai; Xiao-Yu Zuo; Tao Xia; Jie-Rong Chen; Li-Na Feng; Jing Quan Lim; Shu-Wei Chen; Mu-Sheng Zeng; Yun-Miao Guo; Bo Li; Xiao-Jun Xia; Yi Xia; Yurike Laurensia; Burton Kuan Hui Chia; Hui-Qiang Huang; Ken He Young; Soon Thye Lim; Choon Kiat Ong; Yi-Xin Zeng; Jin-Xin Bei
Journal:  Leukemia       Date:  2018-12-13       Impact factor: 11.528

Review 8.  Epstein barr virus encodes miRNAs to assist host immune escape.

Authors:  Weiming Li; Cong He; Jiayi Wu; Dazhi Yang; Weihong Yi
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207

9.  Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Disorders Manifested as Gastrointestinal Perforations and Skin Lesions: A Case Report.

Authors:  Hai-Juan Xiao; Ji Li; Hong-Mei Song; Zheng-Hong Li; Mei Dong; Xiao-Ge Zhou
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 10.  Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases.

Authors:  Hiroshi Kimura; Shigeyoshi Fujiwara
Journal:  Front Pediatr       Date:  2019-01-04       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.